Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: A European model based on the CLARITY and COMMIT trials

Clinical Therapeutics

Volumn 29, Issue 6, 2007, Pages 1184-1202

  Berg, Jenny ^a   Lindgren, Peter ^a   Spiesser, Julie ^b   Parry, David ^c   Jönsson, Bengt ^d  

^a European Health Economics   (Sweden)

^b SANOFI   (France)

^c BRISTOL MYERS SQUIBB   (United States)

^d STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

clopidogrel; cost effectiveness; decision model; Europe; ST segment elevation myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; METOPROLOL;

ARTICLE; BLEEDING; CLINICAL TRIAL; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DRUG FATALITY; EUROPE; GASTROINTESTINAL HEMORRHAGE; GERMANY; HEART INFARCTION; HEART REINFARCTION; HUMAN; PROBABILITY; SENSITIVITY ANALYSIS; ST SEGMENT ELEVATION; STROKE; SWEDEN; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS;

AGED; COHORT STUDIES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG UTILIZATION REVIEW; FEMALE; FRANCE; GERMANY; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; SWEDEN; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 34547588051     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.06.020     Document Type: Article

References (39)

1. for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Yusuf S., Zhao F., Mehta S., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [published corrections appear in N Engl J Med. 2001;345:1506 and 1716]. N Engl J Med 345 (2001) 494-502
2. for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators. Mehta S., Yusuf S., Peters R., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 358 (2001) 527-533
3. for the CREDO Investigators (Clopidogrel for the Reduction of Events During Observation). Steinhubl S., Berger P., Mann III J., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial [published correction appears in JAMA. 2003;289:987]. JAMA 288 (2002) 2411-2420
4. for the CLARITY-TIMI 28 Investigators. Sabatine M., Cannon C., Gibson C., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
5. for the COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Chen Z., Jiang L., Chen Y., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
6. Lindgren P., Jonsson B., and Yusuf S. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: A long-term model based on the CURE trial. J Intern Med 255 (2004) 562-570
7. Lindgren P., Stenestrand U., Malmberg K., and Jonsson B. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Clin Ther 27 (2005) 100-110
8. Ringborg A., Lindgren P., and Jonsson B. The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: A Swedish analysis of the CREDO trial. Eur J Health Econ 6 (2005) 354-362
9. Detsky A., Naglie G., Krahn M., et al. Primer on medical decision analysis: Part 2-building a tree. Med Decis Making 17 (1997) 126-135
10. Sonnenberg F., and Beck J. Markov models in medical decision making: A practical guide. Med Decis Making 13 (1993) 322-338
11. for the GUSTO-IIb investigators. Armstrong P., Fu Y., Chang W., et al. Acute coronary syndromes in the GUSTO-IIb trial: Prognostic insights and impact of recurrent ischemia. Circulation 98 (1998) 1860-1868
12. Singh M., Reeder G., Jacobsen S., et al. Scores for post-myocardial infarction risk stratification in the community. Circulation 106 (2002) 2309-2314
13. for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Yusuf S., Mehta S., Zhao F., et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 107 (2003) 966-972
14. Swedish National Board of Health and Welfare. Hospital Discharge Register and Cause of Death Register (2003)
15. US Dept of Health and Human Services, Centers for Disease Control and Prevention, and National Cen ter for Health Statistics (NCHS). Inter national Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) (2003), NCHS, Hyattsville, Md
16. World Health Organization (WHO). International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). 2nd ed (2004), WHO, Geneva, Switzerland
17. Ekman M. Consumption and production by age in Sweden: Basic facts and health economic implications [dissertation]. In: Ekman M. (Ed). Studies in Health Economics: Modelling and Data Analysis of Costs and Survival (2002), Stockholm School of Economics, Stockholm, Sweden
18. Burstrom K., Johannesson M., and Diderichsen F. Health-related quality of life by disease and socio-economic group in the general population in Sweden. Health Policy 55 (2001) 51-69
19. www.fass.se
20. Zethraeus N., Molin T., Henriksson P., and Jonsson B. Costs of coronary heart disease and stroke: The case of Sweden. J Intern Med 246 (1999) 151-159
21. Levy E., Gabriel S., and Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmaco Economics 21 (2003) 651-659
22. Bruggenjurgen B., Rupprecht H., Willich S., et al. Cost of atherothrombotic diseases-myocardial infarction, ischaemic stroke and peripheral arterial occlusive disease-in Germany. J Public Health 13 (2005) 216-224
23. Rossnagel K., Nolte C., Muller-Nordhorn J., et al. Medical resource use and costs of health care after acute stroke in Germany. Eur J Neurol 12 (2005) 862-868
24. Kolominsky-Rabas P., Heuschmann P., Marschall D., et al. Lifetime cost of ischemic stroke in Germany: Results and national projections from a population-based stroke registry: The Erlangen Stroke Project. Stroke 37 (2006) 1179-1183
25. Spieler J., Lanoe J., and Amarenco P. Costs of stroke care according to handicap levels and stroke subtypes. Cerebrovasc Dis 17 (2004) 134-142
26. Johannesson M. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?. Eur Heart J 22 (2001) 919-925
27. www.srvn.org/prislista.htm
28. Main Economic Indicators: Consumer Prices (2006), Organisation for Economic Co-operation and Development, Paris, France
29. www.scb.se/templates/tableorchart_33847.asp
30. Eurostat. Euro/ECU exchange rates. Available at: (2006). www.epp.eurostat.ec.europa.eu/portal/page?_pageid=1996,45323734_dad=portal_schema=PORTALscreen=welcomerefopen=/product=eu_master_exchange_ra March 9
31. Johannesson M. The cost effectiveness of hypertension treatment in Sweden. PharmacoEconomics 7 (1995) 242-250
32. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16 (1997) 33-64
33. Available at: http://www.mortality.org. Accessed February 20, 2006. University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany). The Human Mortality Database (2003)
34. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (2003)
35. Lothgren M., and Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 9 (2000) 623-630
36. Eichler H., Kong S., Gerth W., et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge?. Value Health 7 (2004) 518-528
37. Harland J., Unwin N., Bhopal R., et al. Low levels of cardiovascular risk factors and coronary heart disease in a UK Chinese population. J Epidemiol Community Health 51 (1997) 636-642
38. Woo K., Chook P., Young R., and Sanderson J. New risk factors for coronary heart disease in Asia. Int J Cardiol 62 Suppl 1 (1997) S39-S42
39. for the GRACE Investigators. Fox K., Goodman S., Anderson Jr. F., et al. From guidelines to clinical practice: The impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24 (2003) 1414-1424